Showing results (1501-1510 of 1,549) with videos related to
Sort By:
Pageof 155
The Journal of Dermatological Treatment|February 6, 2026
Real-world effectiveness and safety of guselkumab in adult patients with facial and/or genital psoriasis: a 52-week analysis from the Italian multicentric GULLIVER studyClaudio Bonifati, Giuseppe Argenziano, Serena Lembo, et al.Journal of Diabetes and Metabolic Disorders|March 29, 2019
Correction to: The basal to total insulin ratio in outpatients with diabetes on basal-bolus regimenElena Castellano, R Attanasio, V A Giagulli, et al.Journal of Diabetes and Metabolic Disorders|March 29, 2019
The basal to total insulin ratio in outpatients with diabetes on basal-bolus regimenElena Castellano, R Attanasio, V A Giagulli, et al.Journal of the European Academy of Dermatology and Venereology : JEADV|June 26, 2024
Effectiveness of guselkumab in patients with facial and/or genital psoriasis: Interim analysis results at Week 12 from the GULLIVER studyC Bonifati, S Lembo, A G Richetta, et al.Global & Regional Health Technology Assessment|January 17, 2024
A pharmacoeconomic analysis from Italian guidelines for the management of prolactinomasMichele Basile, Ilaria Valentini, Roberto Attanasio, et al.Dermatology and Therapy|January 11, 2021
Treat-to-Target Approach for the Management of Patients with Moderate-to-Severe Plaque Psoriasis: Consensus RecommendationsPaolo Gisondi, Marina Talamonti, Andrea Chiricozzi, et al.Journal of Anxiety Disorders|December 28, 2024
Exposure therapy consortium: Outcomes of the proof-of-principle studyJasper A J Smits, Jonathan S Abramowitz, Rebecca A Anderson, et al.Journal of Endocrinological Investigation|July 23, 2025
Italian guidelines for the management of adult individuals with primary hypothyroidism outside pregnancyRinaldo Guglielmi, Caterina Mian, Roberto Novizio, et al.Clinical, Cosmetic and Investigational Dermatology|December 18, 2023
Long-Term Drug Survival and Effectiveness of Secukinumab in Patients with Moderate to Severe Chronic Plaque Psoriasis: 42-Month Results from the SUPREME 2.0 StudyFilomena Russo, Marco Galluzzo, Luca Stingeni, et al.Endocrine, Metabolic & Immune Disorders Drug Targets|April 22, 2024
Italian Guidelines for the Management of Sporadic Primary HyperparathyroidismFabio Vescini, Giorgio Borretta, Iacopo Chiodini, et al.Pageof 155